Drug Trial Radar · NCT01583426
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
Last checked: Nov 20, 2026Latest source record: Aug 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,229
Actual
Start
Jul 2012
Primary completion
Dec 2018
Study completion Dec 2018
Sponsor
- Lead sponsor
- GBG Forschungs GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Celgene Corporation; Roche Pharma AG
- First posted
- Apr 24, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Current guidelines as those from the AGO-Breast commission recommend for neoadjuvant breast cancer patients either a sequence of 4 cycles EC followed by 4 cycles of a taxane or 6 cycles of TAC based on previous large scale studies. Treatment of patients with HER2-positive disease should include also simultaneous application of trastuzumab. Solvent-based taxanes (paclitaxel, docetaxel) cause severe toxicities not only by the active agents itself but also by the solvents like cremophor. Nab-paclitaxel (Abraxane®) is a solvent-free formulation of paclitaxel encapsulated in albumin. It does not require premedication with corticosteroids or antihistamines to prevent the risk of solvent-mediated hypersensitivity reactions. This new formulation improves safety profile, allows higher dosing with shorter infusion duration, and produces higher tumor drug concentration. As neoadjuvant treatment does not only allow to compare competing treatment approaches with a very high quality (homogenous treatment population, precise assessment of response by histological assessment), but also to identify predictive markers, this trial will compare weekly nab-paclitaxel with solvent-based paclitaxel at their currently optimal doses. In case of HER2-positive tumor status patients receive Pertuzumab and Trastuzumab additionally.
Conditions
- Tubular Breast Cancer Stage II
- Mucinous Breast Cancer Stage II
- Breast Cancer Female NOS
- Invasive Ductal Breast Cancer
- Tubular Breast Cancer Stage III
- HER-2 Positive Breast Cancer
- Inflammatory Breast Cancer Stage IV
- Inflammatory Breast Cancer
Interventions
nab-PaclitaxelDrug
nab-Paclitaxel 125 mg/m² weekly for 12 weeks
PaclitaxelDrug
Paclitaxel 80 mg/m² weekly for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological complete response (pCR=ypT0 ypN0) rates of neoadjuvant treatment of nab-paclitaxel with solvent-based paclitaxel as part of neoadjuvant treatment of operable or locally advanced primary breast cancer.Time frame: 24 weeks (time window + 3 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Helios-Klinikum Berlin-Buch
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.